Research Article

Pentraxin 3 Released from Neutrophils Increases Plasma Levels in Patients with Acute Coronary Syndrome

Table 1

Characteristics of patients in ACS, VAP, or ASO group.

NormalACSVAPASO

Number7091292637
Age, yr67.7 ± 4.567.8 ± 12.762.2 ± 9.068.1 ± 7.7
Male sex, no. (%)46.871.073.185.7
Smoker, no. (%)Not available81.163.689.7
BMI (≧24.2kg/m2), no%23.931.827.233.3
TCHO, mg/dL208.0 ± 32.8189.5 ± 39.9189.3 ± 37.4201.3 ± 50.8
LDL-c, mg/dL122.1 ± 28.6124.8 ± 36.2103.6 ± 16.6127.8 ± 30.9
HDL-c, mg/dL65.8 ± 16.349.3 ± 12.261.9 ± 14.645.0 ± 11.1
TG, mg/dL108.1 ± 45.3137.3 ± 63.884.2 ± 34.4*141.1 ± 59.1
HgbA1C, %5.5 ± 0.66.0 ± 1.75.1 ± 0.46.1 ± 1.1

Plasma PTX3 (ng/mL)
Arithmetic means2.11 ± 1.605.80 ± 5.33*2.16 ± 0.862.33 ± 1.61

ACS: acute coronary syndrome; VAP: vasospastic angina pectoris; ASO: arteriosclerosis obliterans;BMI: body mass index; TCHO: total cholesterol; LDL-c: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; TG: triglyceride; HgbA1C: hemoglobin A1C; PTX3: pentraxin 3. 𝑃 < 0 . 0 0 0 0 1 .